Approaches to manage ‘affordability’ of high budget impact medicines in key EU countries
Background: The launch of hepatitis C (HCV) drugs such as sofosbuvir or ledipasvir has fostered the question of affordability of novel high budget impact therapies even in countries with high domestic product. European countries have developed a variety of mechanisms to improve affordability of such...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2018-01-01
|
Series: | Journal of Market Access & Health Policy |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/20016689.2018.1478539 |
id |
doaj-4051883c446b407d91b5a131413948f4 |
---|---|
record_format |
Article |
spelling |
doaj-4051883c446b407d91b5a131413948f42020-11-24T22:14:28ZengTaylor & Francis GroupJournal of Market Access & Health Policy2001-66892018-01-016110.1080/20016689.2018.14785391478539Approaches to manage ‘affordability’ of high budget impact medicines in key EU countriesMathias Flume0Marc Bardou1Stefano Capri2Oriol Sola-Morales3David Cunningham4Lars-Ake Levin5Maarten J. Postma6Nicolas Touchot7Kassenärztliche Vereinigung Westfalen-Lippe (KVWL)CHU CHU Dijon-BourgogneCattaneo-LIUC UniversityHealth innovation technology TransferCunningham Healthcare AdvisoryLinköping UniversityUniversity of Groningen, University Medical Center GroningengroupHBackground: The launch of hepatitis C (HCV) drugs such as sofosbuvir or ledipasvir has fostered the question of affordability of novel high budget impact therapies even in countries with high domestic product. European countries have developed a variety of mechanisms to improve affordability of such therapies, including ‘affordability thresholds’, price volume agreements or caps on individual product sales, and special budgets for innovative drugs. While some of these mechanisms may help limit budget impact, there are still significant progresses to be made in the definition and implementation of approaches to ensure affordability, especially in health systems where the growth potential in drug spending and/or in the patient contribution to health insurance are limited. Objectives: In this article, we will review how seven countries in western Europe are approaching the question of affordability of novel therapies and are developing approaches to continue to reward new sciences while limiting budget impact. We will also discuss the question of affordability of cost-effective but hugely expensive therapies and the implications for payers and for the pharmaceutical industry. Results: There is clearly not one solution that is used consistently across countries but rather a number of ‘tools’ that are combined differently in each country. This illustrates the difficulty of managing affordability within different legal frameworks and within different health care system architectures.http://dx.doi.org/10.1080/20016689.2018.1478539Budget impactaffordabilitycost effectivenessmarket accessfundingexpensive therapieshealth technology assessmentprice negotiation |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Mathias Flume Marc Bardou Stefano Capri Oriol Sola-Morales David Cunningham Lars-Ake Levin Maarten J. Postma Nicolas Touchot |
spellingShingle |
Mathias Flume Marc Bardou Stefano Capri Oriol Sola-Morales David Cunningham Lars-Ake Levin Maarten J. Postma Nicolas Touchot Approaches to manage ‘affordability’ of high budget impact medicines in key EU countries Journal of Market Access & Health Policy Budget impact affordability cost effectiveness market access funding expensive therapies health technology assessment price negotiation |
author_facet |
Mathias Flume Marc Bardou Stefano Capri Oriol Sola-Morales David Cunningham Lars-Ake Levin Maarten J. Postma Nicolas Touchot |
author_sort |
Mathias Flume |
title |
Approaches to manage ‘affordability’ of high budget impact medicines in key EU countries |
title_short |
Approaches to manage ‘affordability’ of high budget impact medicines in key EU countries |
title_full |
Approaches to manage ‘affordability’ of high budget impact medicines in key EU countries |
title_fullStr |
Approaches to manage ‘affordability’ of high budget impact medicines in key EU countries |
title_full_unstemmed |
Approaches to manage ‘affordability’ of high budget impact medicines in key EU countries |
title_sort |
approaches to manage ‘affordability’ of high budget impact medicines in key eu countries |
publisher |
Taylor & Francis Group |
series |
Journal of Market Access & Health Policy |
issn |
2001-6689 |
publishDate |
2018-01-01 |
description |
Background: The launch of hepatitis C (HCV) drugs such as sofosbuvir or ledipasvir has fostered the question of affordability of novel high budget impact therapies even in countries with high domestic product. European countries have developed a variety of mechanisms to improve affordability of such therapies, including ‘affordability thresholds’, price volume agreements or caps on individual product sales, and special budgets for innovative drugs. While some of these mechanisms may help limit budget impact, there are still significant progresses to be made in the definition and implementation of approaches to ensure affordability, especially in health systems where the growth potential in drug spending and/or in the patient contribution to health insurance are limited. Objectives: In this article, we will review how seven countries in western Europe are approaching the question of affordability of novel therapies and are developing approaches to continue to reward new sciences while limiting budget impact. We will also discuss the question of affordability of cost-effective but hugely expensive therapies and the implications for payers and for the pharmaceutical industry. Results: There is clearly not one solution that is used consistently across countries but rather a number of ‘tools’ that are combined differently in each country. This illustrates the difficulty of managing affordability within different legal frameworks and within different health care system architectures. |
topic |
Budget impact affordability cost effectiveness market access funding expensive therapies health technology assessment price negotiation |
url |
http://dx.doi.org/10.1080/20016689.2018.1478539 |
work_keys_str_mv |
AT mathiasflume approachestomanageaffordabilityofhighbudgetimpactmedicinesinkeyeucountries AT marcbardou approachestomanageaffordabilityofhighbudgetimpactmedicinesinkeyeucountries AT stefanocapri approachestomanageaffordabilityofhighbudgetimpactmedicinesinkeyeucountries AT oriolsolamorales approachestomanageaffordabilityofhighbudgetimpactmedicinesinkeyeucountries AT davidcunningham approachestomanageaffordabilityofhighbudgetimpactmedicinesinkeyeucountries AT larsakelevin approachestomanageaffordabilityofhighbudgetimpactmedicinesinkeyeucountries AT maartenjpostma approachestomanageaffordabilityofhighbudgetimpactmedicinesinkeyeucountries AT nicolastouchot approachestomanageaffordabilityofhighbudgetimpactmedicinesinkeyeucountries |
_version_ |
1725798740751548416 |